{"id":"W3088595788","doi":"10.1016/j.annonc.2020.08.2246","title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Internal medicine; Hazard ratio; Fulvestrant; Population; Aromatase inhibitor; Progression-free survival; Oncology; Breast cancer; Cancer; Chemotherapy; Aromatase; Confidence interval; Estrogen receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001743771,0.001241791,0.0017703,0.0005227961,0.0004211339,0.0008938935,0.0009882437,0.0008249945,0.004671324],"category_scores_gemma":[0.0007045805,0.0003442352,0.002159094,0.0004646989,0.0006585468,0.0006255395,0.000356282,0.002828355,0.001289863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008170565,"about_ca_system_score_gemma":0.001151852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001120642,"about_ca_topic_score_gemma":0.003490242,"domain_scores_codex":[0.9995204,0.0002249307,0.00002829107,0.00006669616,0.00006828093,0.00009140398],"domain_scores_gemma":[0.999358,0.0001259485,0.0001286399,0.00005302025,0.00004921749,0.0002851367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6416303,0.03428002,0.02381914,0.001285698,0.005129851,0.0002278039,0.0002492874,0.005376937,0.0421575,0.0005227993,0.01876916,0.2265515],"study_design_scores_gemma":[0.3885548,0.4931552,0.08060233,0.0001484544,0.005520646,0.0006906081,0.0001326222,0.002614471,0.009010371,0.0005590509,0.01894068,0.00007078222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769872,0.006347747,0.0007258842,0.00079009,0.0002304784,0.00103856,0.007350349,0.0002252566,0.00630446],"genre_scores_gemma":[0.9547058,0.004659364,0.002541932,0.001730194,0.0003295995,0.001821051,0.02669147,0.0001780572,0.007342544],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004671324,"threshold_uncertainty_score":0.01562715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07991196063309068,"score_gpt":0.3941266836991093,"score_spread":0.3142147230660186,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}